Clinical Trial Update: CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CD56+CD3- natural killer cells following allogeneic stem cell transplantation in hematologic malignancies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• CD56+CD3- NK cells (CD56+CD3- NK cells)

Snippet

Sponsor: Imperial College London | Conditions: Haematological Malignancies, Allogeneic Stem Cell Transplant | Phase 1 | Status: WITHDRAWN